Accession Number: | 0001209191-23-007364 |
Date: | 2023-02-03 |
Issuer: | ATYR PHARMA INC (LIFE) |
Original Submission Date: |
BROADFOOT JILL MARIE
3545 JOHN HOPKINS COURT, SUITE 250
SAN DIEGO, CA 92121
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2023-02-03 | M | 3,750 | a | $0.00 | 17,026 | direct | ||
COMMON STOCK | 2023-02-06 | S | 1,566 | d | $2.36 | 15,460 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
RESTRICTED STOCK UNIT | 0.0 | 2023-02-03 | deemed execution date | M | 3,750 (d) | common stock 3,750 | $0.00 | 11,250 | direct |
ID | footnote |
---|---|
f1 | represents shares acquired upon the vesting of restricted stock units (rsus) granted to the reporting person on february 3, 2022. |
f2 | restricted stock units convert into common stock on a one-for-one basis. |
f3 | includes 986 shares acquired under that company's 2015 employee stock purchase plan on november 15, 2022. |
f4 | sale made by the reporting person to satisfy tax withholding obligations in connection with the partial vesting of rsus granted on february 3, 2022. |
f5 | the rsus vest in four equal annual installments beginning on february 3, 2023, such that the rsus will fully vest on february 3, 2026. the rsus are subject to accelerated vesting upon termination without cause upon a change of control of the issuer. |